Acquired resistance to the anti-proliferative effect of interleukin-1 and interleukin-6 is a recessive phenotype in A375 human melanoma cells

Melanoma Research

Volumn 7, Issue 6, 1997, Pages 455-462

  Itoh, S ^a   Hayashi, H ^a   Yang, D ^a   Takii, T ^a   Onozaki, K ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Cytokine resistance; Interleukin 1; Interleukin 6; Melanoma; Somatic cell hybridization

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6;

ARTICLE; CANCER RESISTANCE; CELL HYBRIDIZATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PHENOTYPE; PRIORITY JOURNAL; SOMATIC CELL;

CELL DIVISION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYBRID CELLS; INTERLEUKIN-1; INTERLEUKIN-6; MELANOMA; PHENOTYPE; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031404569     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199712000-00003     Document Type: Article

References (30)

1. Swope VB, Abdel MZ, Kassem LM, et al. Interleukin 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Derinatol 1991; 96: 180-185.
2. Lu C, Kerbel RS. Cytokine, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. Ciirr Opin Oncol 1994; 6: 212-222.
3. Dinarello CA. Tlie interleukin-1 family: 10 years of discover)'. FASEBJ 1994; 8: 1314-1325.
4. Gery I, Gershon RK, Waksman DH. Potentiation of the T lymphocyte response to mitogens. I. The responding cell. J Exp Meet 1972; 136: 128-142.
5. Schmidt JA, Mizel SB, Cohen D, et al. Interleukin 1, a potent regulator of fibroblast proliferation. / Immitnol 1982; 128: 2177-2182.
6. Gaffney EV, Tsai SC. Lymphocyte-activating and growth inhibitor)' activities for several sources of native and recombinant interleukin 1. Cancer Res 1986; 46: 3834-3837.
7. Onozaki K, Tamatani T, Hashimoto T, et al. Growth inhibition and augmentation of mouse myeloid leukemic cell line differentiation by interleukin 1. Cancer Res 1987; 47: 2397-2402.
8. Maier JAM, Voulalas P, Roeder D, et al. Extension of / the life-span of human endothelial cells by an interleukin-la antisense oligomer. Science 1990; 249: 1570-1574.
9. Onozaki K, Matsushima K, Aggarwal BB, et al. Human interleukin 1 is a cytocidal factor for several tumor cell lines. Jlmmunol 1985; 135: 3962-3968.
10. Araki M, Yano T, Hayashi H, et al. Resistance to the anti-proliferative effect of IL-1 on human melanoma cell line is associated with endogenous production of IL-1 and IL-6. IntJ Cancer 1994; 56: 275-280.
11. Onozaki K, Araki M, Shimizu R, et al. Resistance of human melanoma cells to the antiproliferative effect of IL-1 includes endogenous production of IL-1 and IL6 and possible deficiency of IL-5R-mediated signal transduction. Cancer Detect Prev 1995; 19: 56.
12. Itoh S, Hayashi H, Watanabe N, et al. Interleukin 1 (IL1) production is not essential for acquired resistance of human melanoma cells A375 to anti-proliferative effect of IL-1. IntJ Cancer 1996; 65: 805-811. 13- Hayashi H, Shimizu R, Fujii K, et al. Resistance to IL-1 anti-proliferative effect, accompanied by characteristics of advanced melanoma, permits invasion of human melanoma cells in vitro, but not metastasis in the nude mouse. IntJ Cancer 1997; 72: 1-6.
13. Chapekar MS, Huggett AC, Cheng CC, et al. Isolation and characterization of a rat liver epithelial cell line resistant to the antiproliferative effects of transforming growth factor ß(type 1). Cancer Res 1990; 50: 3600-3604.
14. Spriggs D, Imamura K, Rodriguez C, et al. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci USA 1987; 84: 6563-6566.
15. Himeno T, Watanabe N, Yamauchi N, et al. Expression of endogenous tumor necrosis factor as a protective protein against the cytotoxicity of exogenous tumor necrosis factor. Cancer Res 1990; 50: 4941-4945.
16. Ito M, Isuhara M, Shimizu K, et al. Metastatic phenotype in hybrid cells derived from B16 melanoma. Cancer Lett 1994; 78: 33-39-
17. Ethier SP, Taback E. Insulin like growth factor-I independence in rat mammary carcinoma cells: a dominant phenotype in somatic cell hybrid. Cancer Lett 1993; 74: 189-195.
18. Yang D, Hayashi H, Hiyama H, et al. Transfection of human melanoma cells with type I interleukin-l (IL-1) receptor cDNA rendered them IL-1-responsive and ' revealed the importance of ODC activity down-regulation in IL-1-induced growth inhibition. / Biochem 1995; 118: 802-809-
19. Galfre G, Howe SC, Milstein C, et al. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 1977; 266: 550-552.
20. Ruff MR, Gifford GE. Purification and physicochemical characterization of rabbit tumor necrosis factor./ Immimol 1980; 125: 1671-1677.
21. Hopkins SJ, Humphreys M. Simple, sensitive and specific bioassay of interleukin-l. / Immunol Methods 1989; 120: 271-276.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. / Immunol Methods 1983; 65: 55-63.
23. Matsuda T, Hirano T, Kishimoto T. Establishment of an interleukin 6/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. EurJ Immunol 1989; 18: 951-956.
24. Nophar Y, Holtmann H, Ber R, et al. Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. J Immunol 1988; 140: 3456-3460.
25. Hirose K, Longo DL, Oppenheim JJ, et al. Overexpression of mitochondrial manganese Superoxide dismutase promotes the survival of tumor cells exposed to interleukin 1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEBJ 1993; 7: 361-368.
26. Mehlen P, Preville X, Chareyron P, et al. Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNFand oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. / Immunol 1995; 154: 363-374.
27. Bani MR, Rak J, Adachi D, et al. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 1996; 56: 3075-3086.
28. Endo Y, Matsushima K, Onozaki K, et al. Role of ornithine decarboxylase in the regulation of cell growth by IL-1 and tumor necrosis factor. / Immunol 1988; 141: 2342-2348.
29. Yang D, Hayashi H, Takii T, et al. Interleukin-1-induced growth inliibition of human melanoma cells. J Biol Chem 1997; 272: 3376-3383.
30. Manson JC, Symons JA, Di Giovine FS, et al. Autoregulation of interleukin 1 production. Eur J Immunol 1989; 19: 261-265.